UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
13
March 2026 - “Director/PDMR Shareholding”
|
99.1
Haleon plc: Director/PDMR
Shareholding
13 March 2026: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
notification and public disclosure in accordance with the
requirements of The UK Market Abuse Regulation of Transactions by
Persons Discharging Managerial Responsibilities
("PDMRs").
This notification sets out the details of the grant of Haleon share
awards over Ordinary Shares made to PDMRs under the Haleon
Performance Share Plan and Deferred Annual Bonus Plan.
The Performance Share Plan main awards
are subject to performance conditions over the performance period
ending on 31 December 2028. Performance targets are disclosed in
the 2025 Annual Report and 20-F.
All awards were made in line with the principles of Haleon's
Directors' Remuneration Policy and are
subject to malus and clawback provisions.
|
1
|
Details of the issuer or emission allowance market
participant
|
|||||
|
a)
|
Name of the entity
|
Haleon plc
|
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Executive Officer
|
||||
|
b)
|
Initial notification /Amendment to prior
notifications
|
Initial Notification
|
||||
|
3
|
Details of the person discharging managerial responsibilities /
person closely associated ("PCA")
|
|||||
|
a)
|
PDMR/PCA
|
PDMR
|
||||
|
b)
|
Name
|
Brian McNamara
|
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|||||
|
a)
|
Description of Instrument
|
Share
|
||||
|
|
|
|||||
|
Identification code
|
GB00BMX86B70
|
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i)
Grant of a conditional award under the Haleon plc Performance Share
Plan
(ii)
Grant of a conditional award under the Haleon plc Deferred Annual
Bonus Plan
|
||||
|
c)
|
Currency, Price(s) and Volume(s)
|
|
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
(i)
|
Nil
|
1,639,855
|
|
|
|
|
|
(ii)
|
Nil
|
173,825
|
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information
|
|
||||
|
|
|
|||||
|
- Aggregated volume
|
1,813,680
|
|||||
|
|
|
|||||
|
- Price
|
Nil
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
12 March 2026
|
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
|
1
|
Details of the issuer or emission allowance market
participant
|
|||||
|
a)
|
Name of the entity
|
Haleon plc
|
||||
|
b)
|
LEI
|
549300PSB3WWEODCUP19
|
||||
|
2
|
Reason for the notification
|
|||||
|
a)
|
Position/status
|
Chief Financial Officer
|
||||
|
b)
|
Initial notification /Amendment to prior
notifications
|
Initial Notification
|
||||
|
3
|
Details of the person discharging managerial responsibilities /
person closely associated ("PCA")
|
|||||
|
a)
|
PDMR/PCA
|
PDMR
|
||||
|
b)
|
Name
|
Dawn Allen
|
||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
|||||
|
a)
|
Description of Instrument
|
Share
|
||||
|
|
|
|||||
|
Identification code
|
GB00BMX86B70
|
|||||
|
|
|
|||||
|
b)
|
Nature of the transaction
|
(i)
Grant of a conditional award under the Haleon plc Performance Share
Plan
(ii)
Grant of a conditional award under the Haleon plc Deferred Annual
Bonus Plan
|
||||
|
c)
|
Currency, Price(s) and Volume(s)
|
|
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
|
(i)
|
Nil
|
712,784
|
|
|
|
|
|
(ii)
|
Nil
|
95,513
|
|
|
|
|
|
|
|
|
||
|
d)
|
Aggregated information
|
|
||||
|
|
|
|||||
|
- Aggregated volume
|
808,297
|
|||||
|
|
|
|||||
|
- Price
|
Nil
|
|||||
|
|
|
|||||
|
e)
|
Date of the transaction
|
12 March 2026
|
||||
|
f)
|
Place of the transaction
|
Outside a trading venue
|
||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused
on better everyday health. Our people, our brands, our research,
our investment and our innovation are aimed at improving the
everyday health of consumers. Our product portfolio spans six major
categories - Oral Health, Vitamins, Minerals and Supplements (VMS),
Pain Relief, Respiratory Health, Digestive Health and Therapeutic
Skin Health and Other. Our superior brands - such
as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion
consumers and are recommended by health professionals around the
world.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
March 13, 2026
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|